Scopus BioPharma Issues Open Letter to Stockholders Detailing Morris Laster’s Campaign Against the Company

NEXT STORY
Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19
PREV STORY
Century Therapeutics Added to the NASDAQ Biotechnology Index
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Innocoll Holdings plc Announces the Completion of Enrollment in Two Pivotal Phase 3 Clinical Trials of COGENZIA for the Treatment of Diabetic Foot Infections

ATHLONE, Ireland, June 23, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, ...

author_avatar
NASDAQ Market News

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

author_avatar
NASDAQ Market News

Global Gene Therapy Market Report 2020: Market is Expected to Recover and Reach $6.84 Billion in 2023 – Forecast to 2030

author_avatar
NASDAQ Market News